Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2641-2647

  Hope, R ^a   Blackburn, R M ^a   Verlander, N Q ^a   Johnson, A P ^a   Kearns, A ^a   Hill, R ^a   Hopkins, S ^a,b,d   Sheridan, E ^a   Livermore, D M ^a,c   Scarborough, M ^d   Majumdar, S ^d   Cunniffe, J ^d   Farrington, M ^d   Gouliouris, T ^d   Marodi, C ^d   Godwin, P ^d   Tuck, A ^d   Warren, R ^d   Coe, P ^d   Hassan, I ^d   Mannion, P ^d   Loudon, K ^d   Youngs, E ^d   Johnson, A ^d   Lee, M ^d   Weston, V ^d   Guleri, A ^d   Howe, R ^d   Matthew, D ^d   Cotterill, S ^d   Todd, N ^d   Patel, B ^d   Mlangeni, D ^d   Stockley, J M ^d   Spencer, R ^d   Gardner, J ^d   Thwaites, G ^d   Kirby, A ^d   Crook, D ^d   Llewellyn, M ^d   Price, J ^d   Morris Jones, S ^d   Tilley, R ^d   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d NONE

Author keywords

BSAC; CLSI; EMRSA 15; Mortality

Indexed keywords

RIFAMPICIN; VANCOMYCIN;

AGAR DILUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLONAL VARIATION; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; INFUSION SYSTEM; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PACEMAKER; PENICILLIN RESISTANCE; PREDICTIVE VALUE; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

BSAC; CLSI; EMRSA-15; MORTALITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROGNOSIS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84886306687     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt234     Document Type: Article

References (35)

1. Andrews JM, Howe RA. BSAC standardized disc susceptibility testing method (version 10). J Antimicrob Chemother 2011; 66: 2726-57.
2. Andrews JM, for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother 2008; 62: 256-78.
3. EUCAST.http://www.eucast.org/(1 July 2012, date last accessed).
4. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
5. Moise-Broder PA, Sakoulas G, Forrest A et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51: 2582-6.
6. Gould I.M. Theproblemwithglycopeptides. Int J AntimicrobAgents2007;30: 1-3.
7. Wootton M, Walsh T.R., MacGowan AP. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3982-3.
8. Ellington M.J, Hope R, Livermore DM et al. Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007. J Antimicrob Chemother 2010; 65: 446-8.
9. Burnie J, Matthews R, Jiman-Fatami A et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000; 31: 684-9.
10. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI,Wayne, PA, USA, 2005.
12. Ellington MJ, Perry C, Ganner M et al. Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England andWales. Eur J Clin Microbiol Infect Dis 2009; 28: 1113-21.
13. Harmsen D, Claus H, Witte W et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003; 41: 5442-8.
14. Ridom SpaServer.http://www.spaserver.ridom.de(13 August 2012, date last accessed).
15. Monecke S, Coombs G, Shore AC et al. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PLoS One 2011; 6: e17936.
16. Holland TL, Fowler VG Jr. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis 2011; 204: 329-31.
17. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
18. Maclayton DO, Suda KJ, Coval KA et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 mg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006; 28: 1208-16.
19. Neoh HM, Hori S, Komatsu M et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007; 6: 13.
20. Lodise TP,Graves J, EvansAet al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
21. Soriano A, Marco F, Martinez JA et al. Influence of vancomycinminimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
22. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
23. Wang JL, Wang JT, Sheng WH et al. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC2 mg/L, by the broth microdilution method. BMC Infect Dis 2010; 10: 159.
24. Yoon YK, Kim JY, Park DW et al. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65: 1015-8.
25. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
26. Kullar R, Davis SL, Levine DP et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-81.
27. Price J, Atkinson S, LlewelynMet al. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48: 997-8.
28. Hsu DI, Hidayat LK, Quist R et al. Comparison of methodspecific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32: 378-85.
29. Crompton JA, North DS, YoonM et al. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother 2010; 65: 1784-91.
30. Honda H., Doern C.D., Michael-Dunne W. Jr et al. Theimpact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11: 335.
31. Han JH, Mascitti KB, Edelstein PH et al. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2012; 56: 5164-70.
32. Walraven CJ, North MS, Marr-Lyon L et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 2386-92.
33. Holmes NE, Turnidge JD, Munckhof WJ et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204: 340-7.
34. BMJ Group and Pharmaceutical Press. British National Formulary. BMJ Publishing Group Ltd, London, and RPS Publishing, London, 2012.
35. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.